Johnson & Johnson Acquires Egea Biosciences
Protein Therapeutics Pioneer to Complement Centocor R&D
The acquisition of Egea, the pioneers of a technology platform designed to optimize protein therapeutics, will strengthen Centocor's position as a leader in biomedicines and protein therapeutics technology. Egea's technology will be used to create product candidates that Centocor can further develop, manufacture and market. The two companies previously announced an exclusive research collaboration on May 13, 2003.
The integration of Egea will enhance Centocor's commitment to protein therapeutics technology and biomedical research and development.
"Bringing together these two innovative companies reflects our common mission of transforming patients' lives through products that treat, and ultimately cure, debilitating or life-threatening diseases," said Jay P. Siegel, M.D., President, Centocor Research & Development. "We share a commitment to patients and health care professionals to pursue solutions to unmet medical needs. Delivering on that commitment begins in laboratories like Egea's. We are extremely fortunate to add to our group the employees of Egea with their passion for innovative biomedical technologies."
Egea Biosciences was founded in 2000 by Glen Evans, M.D., Ph.D. Prior to establishing Egea, Dr. Evans was a leading investigator in the Human Genome Project and held positions at the University of Texas Southwestern Medical Center at Dallas, and at the Salk Institute. Egea's platform technology enables, for the first time, the optimization of biologics and antibodies for therapeutic use through proprietary large-scale gene synthesis.
"We are pleased that Egea's core technology for gene synthesis and protein design will now become an important tool in Centocor's drug development effort," said Glen A. Evans, M.D., Ph.D., Chief Executive Officer and Founder of Egea Biosciences, Inc. "Developing the critical medicines for the future will remain a key focus for Egea's advanced technology platforms."
Other news from the department
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous